CHEMBIO DIAGNOSTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-25: Form 8-K; Period of report 2019-11-25; Description 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; Details 2.01.
- 2019-11-07: Form 8-K; Period of report 2019-11-06; Description 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 1.01.
- 2019-09-09: Form 8-K; Period of report 2019-09-09; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2019-09-05: Form 8-K; Period of report 2019-09-03; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-25 | 8-K | 2019-11-25 | 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure | 2.01 On November 25, 2019, we and our newly formed subsidiary Chembio Diagnostics Brazil LLC, or Chembio Brazil, completed a previously announced acquisition of Orangelife Comercio e Industria Ltda., or Orangelife, pursuant to a quota purchase agreement. 7.01 On November 7, 2019, we issued a press release entitled “[Chembio Diagnostics Announces Completion of Acquisition of Orangelife].” A copy of the press release is furnished as Exhibit 99.1 to this report. | form8k.htm |
| 2019-11-07 | 8-K | 2019-11-06 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.02 On November 7, 2019, we issued a press release announcing financial results for the quarter ended September 30, 2019. 7.01 On November 7, 2019, we issued a press release entitled “Chembio Diagnostics Enters into Definitive Agreement to Acquire Orangelife.” A copy of the press release is furnished as Exhibit 99.2 to this report. | form8k.htm |
| 2019-09-09 | 8-K | 2019-09-09 | 7.01 Regulation FD Disclosure | 7.01 On September 9, 2019, we are posting an investor presentation to our website (www.chembio.com). | form8k.htm |
| 2019-09-05 | 8-K | 2019-09-03 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under “Credit Agreement” in Item 1.01 regarding our entering into, and borrowings under, the Credit Agreement is incorporated herein by reference. 7.01 On September 4, 2019, we issued a press release entitled “Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors.” A copy of the press release is furnished as Exhibit 99.1 to this report. | form8k.htm |
| 2019-08-07 | 8-K | 2019-08-07 | 7.01 Regulation FD Disclosure | 7.01 On August 7, 2019, we are posting an investor presentation to our website (www.chembio.com). | form8k.htm |
| 2019-08-06 | 8-K | 2019-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2019, we issued a press release announcing financial results for the quarter ended June 30, 2019. | form8k.htm |
| 2019-07-18 | 8-K | 2019-07-18 | 8.01 Other Events | 8.01 On July 18, 2019, we announced that we had entered into an agreement with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, to develop a novel point-of-care diagnostic test to detect an undisclosed biomarker. | form8k.htm |
| 2019-06-25 | 8-K | 2019-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 We held our 2019 Annual Meeting of Stockholders on June 18, 2019. | form8k.htm |
| 2019-05-29 | 8-K | 2019-05-29 | 7.01 Regulation FD Disclosure | 7.01 On May 29, 2019, we are posting an investor presentation to our website (www.chembio.com). | form8k.htm |
| 2019-05-01 | 8-K | 2019-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2019, we issued a press release announcing financial results for the quarter ended March 31, 2019. | form8k.htm |
| 2019-04-02 | 8-K | 2019-04-02 | 8.01 Other Events | 8.01 Consistent with our previously announced intention to begin automated production of our DPP tests by the end of the first quarter of 2019, we commenced production of DPP tests on a new, fully automated manufacturing line in March 2019. | form8k.htm |
| 2019-03-25 | 8-K | 2019-03-20 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On March 20, 2019, we entered into an amendment of our existing employment agreement with Javan Esfandiari, our Executive Vice President and Chief Science and Technology Officer. 5.02 On March 20, 2019, we entered into an amendment of our existing employment agreement with Javan Esfandiari, our Executive Vice President and Chief Science and Technology Officer. | form8k.htm |
| 2019-03-08 | 8-K | 2019-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2019, we issued a press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2018. | form8k.htm |
| 2019-03-05 | 8-K | 2019-02-27 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The description set forth in Item 1.01 of this report, and the full text of the Company Lease and Lease and Project Agreement included as Exhibits 10.1 and 10.2 to this report, are incorporated herein by reference. | form8k.htm |
| 2019-02-11 | 8-K | 2019-02-05 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 2.03 The description set forth in the first paragraph of Item 1.01 of this report, and the full text of the lease included as Exhibit 10.1 to this report, are incorporated herein by reference. 5.02 On February 7, 2019, Sharon Klugewicz notified us of her intention to resign as our Senior Vice President and Chief Quality and Regulatory Officer effective as of February 22, 2019. | form8k.htm |
| 2019-01-25 | 8-K | 2019-01-21 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On January 21, 2019, we entered into an amendment of our existing employment agreement with Neil A. Goldman, our Executive Vice President and Chief Financial Officer. 5.02 On January 21, 2019, we entered into an amendment of our existing employment agreement with Neil A. Goldman, our Executive Vice President and Chief Financial Officer. | form8k.htm |
| 2019-01-23 | 8-K/A | 2018-11-06 | 9.01 Financial Statements and Exhibits | 9.01 (a) Financial Statements of Business Acquired. | form8ka.htm |